Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Clinical trial NCT07049926 · RECRUITING
Trial details
- NCT number
- NCT07049926
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-20
- Primary completion
- 2031-10-26
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.